A nitric oxide (NO)–releasing form of aspirin shows promise in animal studies as a way to prevent scarring and reclogging of blood vessels after angioplasty, according to a team of researchers from Italy and the United States (Proc Natl Acad Sci U S A. 2001;98:2860-2864).
Investigators from Italy's University of Naples and University of Salerno; the University of California, Los Angeles, School of Medicine; and the University of California, San Diego, School of Medicine discovered that even low dosages of NCX-4016, the NO–releasing aspirin derivative, were significantly more effective than aspirin alone in reducing postangioplasty restenosis in mice that are genetically prone to develop atherosclerosis when fed a high-cholesterol diet. The protective effect was even greater when the drug was given 1 week before angioplasty.
Stephenson J. Just Say NO to Aspirin? JAMA. 2001;285(10):1283. doi:10.1001/jama.285.10.1283-JWM10002-2-1
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: